Date:September 18, 2012

Kenneth McClain, MD, PhD

Kenneth McClain, M.D., Ph.D.Director, Histiocytosis Program
Texas Children’s Cancer and Hematology Centers

Director, Pediatric Lymphoma-Histiocytosis Fellowship Program

Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Dr. Kenneth McClain
6701 Fannin Street, Suite 1510.11
Houston, TX 77030

Phone: 832-822-4208
Fax: 832-825-1503


About Kenneth McClain, MD, PhD

Dr. Kenneth McClain is Director of the Histiocytosis Program at Texas Children’s Cancer and Hematology Centers. His research is focused on the clinical and biologic aspects of Langerhans cell histiocytosis (LCH). He is a key member of the clinical trials group of the Histiocyte Society.

Dr. McClain and Dr. Carl Allen see 100 new patients with a variety of histiocytic diseases each year. A number of clinical studies are in progress or development including new therapeutic interventions for CNS LCH. Current biologic studies in his lab are focused on determining the gene expression profiles Langerhans cells and lymphocytes from control and patient tissues and making clinical correlations.

Dr. Kenneth McClain is a member of the Lymphoma Program and Director of the Histiocytosis Program.

Learn about Dr. McClain’s Histiocytosis Research


M.D. and Ph.D., University of Chicago School of Medicine
Residency, The Johns Hopkins Hospital
Postdoctoral Research, National Institute of Child Health, Laboratory of Molecular Genetics
Fellowship, University of Minnesota School of Medicine

Board Certifications

American Board of Pediatrics: Pediatrics and Pediatric Hematology/Oncology

Professional Memberships

Past-President, Histiocyte Society
Member, American Society of Hematology (ASH)
Member, American Society of Pediatric Hematology/Oncology (ASPHO)
Past-President, Gulf Coast Hematology Society (GCHS)
Board Member, Histiocytosis Association of America


Society for Pediatric Research, 1986-Present
Visiting Professor of Pediatrics, Charles University, Second Medical Faculty, Motol, Prague, Czech Republic, Conferred 1996.
President, Histiocyte Society 1998-2001
Editorial Board, Medical and Pediatric Oncology 2000-2003
Visiting Professor of Pediatrics. McGill University. April 15-18, 2002
Ph.D. Thesis Opponent. The Karolinska Institute, Stockholm Sweden. May 17, 2002
Selected as one of Best Doctors in America 2003-2008
Texas Super Doctor 2005-2006
Editorial Board: Current Reviews in Pediatrics 2004-Present
AcademicKeys Who’s Who in Medical Sciences


(WWMSE): 2004
Montclair Who’s Who in Healthcare
PDQ Pediatric Treatment Editorial Board 2006-Present
Nesbit Prize for Best Clinical Paper. 23rd Annual Histiocyte Society Meeting
Cambridge England, September 23-25, 2007
Who’s Who 2000, 2009
Best Doctor 2003-2009
Texas Super Doctor 2005-2009

Clinical Special Interests

Hematologic Disorders

Research Interests

Clinical and biologic aspects of Langerhans cell histiocytosis (LCH)
Gene expression profiles


Allen CE, McClain KL. “Erdheim-Chester: beyond the lesion..” Blood. 2011 March 10;117(10):2745-6. Pubmed PMID: 21393495

Kelly C, Salvi S, McClain K, Hayani A. “Hemophagocytic lymphohistiocytosis associated with precursor B acute lymphoblastic leukemia..” Pediatr Blood Cancer. 2011 April;56(4):658-60. Pubmed PMID: 21298755

Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. “How I treat hemophagocytic lymphohistiocytosis..” Blood. 2011 October 13;118(15):4041-52. Pubmed PMID: 21828139

Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, Haroche J, Kaltsas GA, Makras P, Marzano AV, de Menthon M, Micke O, Passoni E, Seegenschmiedt HM, Tazi A, McClain KL. “Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net..” Orphanet J Rare Dis. 2013;8:72. Pubmed PMID: 23672541

Peters TL, McClain KL, Allen CE. “Neither IL-17A mRNA Nor IL-17A Protein Are Detectable in Langerhans Cell Histiocytosis Lesions..” Mol. Ther.. 2011 August;19(8):1433-9. Pubmed PMID: 21654633

Cantu MA, Lupo PJ, Bilgi M, Hicks MJ, Allen CE, McClain KL. “Optimal therapy for adults with langerhans cell histiocytosis bone lesions..” PLoS ONE. 2012;7(8):e43257. Pubmed PMID: 22916233

Rathore N, Eissa HM, Margolin JF, Liu H, Wu MF, Horton T, Kamdar K, Dreyer Z, Steuber P, Rabin KR, Redell M, Allen CE, McClain KL, Guillerman RP, Bollard CM. “Pediatric Hodgkin Lymphoma: Are We Over-scanning Our Patients?.” Pediatr Hematol Oncol. 2012 August;29(5):415-23. PubMed PMID: 22632168

Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. “Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality..” Pediatr Blood Cancer. 2011 January;56(1):154-5. Pubmed PMID: 20842751

Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, Lee ND, Khan SP, Lawrence J, Mo JQ, Bleesing JJ, Filipovich AH, Jordan MB. “Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab..” Pediatr Blood Cancer. 2013 January;60(1):101-9. Pubmed PMID: 22522603

Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S. “Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis..” Blood. 2013 June 20;121(25):5006-14. Pubmed PMID: 23589673

View all publications on PubMed